Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The following reflects the brand's stated target use case combined with the compliance context established above
What this means for the Indian market: Increased accessibility of Semaglutide therapy Greater competition leading to potential price rationalization Expansion of obesity management as a mainstream therapeutic segment A new strategic battleground for pharma marketing teams For healthcare professionals and the pharma industry, this could be one of the most competitive launches in the metabolic segment in the coming years
The cost of GLP-1 RAs remains a barrier, particularly in low- and middle-income countries
The consistency and magnitude of these outcomes explain why over 12% of U.S
Available in doses up to 2.0 mg per week
US$ 23.36
US$ 25.20
US$ 24.30
US$ 24.02
